Literature DB >> 24721680

Clinical implications of distinct metastasizing preferences of different melanoma subtypes.

Nicola L Schoenewolf1, Benedetta Belloni1, Mathew Simcock2, Sabina Tonolla1, Pascale Vogt1, Ellen Scherrer1, David Holzmann3, Reinhard Dummer1.   

Abstract

BACKGROUND: The incidence and mortality of malignant melanoma have been rising during the past decades, the latter being due to the high invasion capacity and the metastatic potential of melanoma cells to distant organs.
OBJECTIVE: We investigated the distribution pattern of melanoma metastases taking into account different clinicopathological subtypes of melanoma.
METHODS: We studied 310 stage IV (AJCC 2009) melanoma patients retrospectively with regard to potential correlations between frequency and occurrence of metastasis and the genetic background and pathological/clinical melanoma subtypes. For all patients, the time to distant metastasis (TTDM) and the distribution patterns of metastases were analyzed and correlated to the median survival time.
RESULTS: Superficially Spreading (SSM) and Nodular melanomas (NMM) spread to the brain more frequently than Acrolentiginous (ALM) and Mucosal (MM) melanomas (p = 0.0012). The preference to affect the skeleton was significantly higher for ALM and MM in comparison to SSM and NMM (p = 0.0049). Lentigo maligna (LMM) tumors showed a significantly lower metastatic spread to distant lymph nodes (p = 0.0159). BRAF mutant versus wildtype tumors showed no significant differences concerning localization of metastasis but patients with BRAF mutant tumors were significantly younger at primary diagnosis and had a significantly shorter stage IV survival (p = 0.0106).
CONCLUSION: This study shows a clear distinction of melanoma subtypes with regard to metastasizing preferences. Further knowledge about melanoma subtype specific characteristics, including molecular markers predictive of homing preferences, may help to understand and manage this heterogeneous disease in terms of prognosis and follow-up procedures.

Entities:  

Keywords:  melanoma metastasis; melanoma subtypes; predictive metastatic patterns; prognostic factors

Mesh:

Year:  2014        PMID: 24721680     DOI: 10.1684/ejd.2014.2292

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  5 in total

1.  Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.

Authors:  C Frenard; L Peuvrel; M Saint Jean; A Brocard; A C Knol; J M Nguyen; A Khammari; G Quereux; B Dreno
Journal:  J Neurooncol       Date:  2015-10-28       Impact factor: 4.130

2.  Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Authors:  Laura J Gardner; Morgan Ward; Robert H I Andtbacka; Kenneth M Boucher; Glen M Bowen; Tawnya L Bowles; Adam L Cohen; Kenneth Grossmann; Ying J Hitchcock; Sheri L Holmen; John Hyngstrom; Hung Khong; Martin McMahon; Marcus M Monroe; Carolyn B Ross; Gita Suneja; David Wada; Douglas Grossman
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

3.  Interdigital Melanoma of the Foot Affecting Two Neighbouring Interdigital Spaces - Second Case Report.

Authors:  Uwe Wollina; Carsten Rilke; Gesina Hansel; Dana Langer; Jacqueline Schönlebe; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2017-07-19

4.  Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis.

Authors:  Ellen C de Heer; Adrienne H Brouwers; Ronald Boellaard; Wim J Sluiter; Gilles F H Diercks; Geke A P Hospers; Elisabeth G E de Vries; Mathilde Jalving
Journal:  EJNMMI Res       Date:  2018-11-20       Impact factor: 3.138

5.  Global DNA demethylation as an epigenetic marker of human brain metastases.

Authors:  Anna-Maria Barciszewska
Journal:  Biosci Rep       Date:  2018-10-22       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.